ASCO News In Brief: Roche Roferon-A
Roche Roferon-A: Helsinki University Hospital Phase III study of recombinant interferon alfa-2a (IFN) with vinblastine (VLB) versus vinblastine alone in 160 patients with advanced renal cell carcinoma shows a seven-month increase in median survival for the IFN/VLB arm (15.8 months v. 8.8 months). Objective response rates were 16% for IFN/VLB and 2.5% for VLB alone. Median time to progression was 3 months in the IFN/VLB arm and 2.1 months in the VLB arm. Reversible granulocytopenia was experienced by 12 of 79 patients in the IFN/VLB arm...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth